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Abstract
In-silico prediction of repurposable drugs is an effective drug discovery strategy which
supplements de-nevo drug discovery from scratch. Lack of severe side effects of
repurposable drugs in other applications and most importantly the reduced time frame
in development suits the urgency of the situation in general. Most recent, and most
advanced artificial intelligence (AI) approaches have boosted drug repurposing in terms
of throughput and accuracy enormously. But, with the growing number of drugs,
targets and their huge interactions produce imbalance data which may not be suitable
to directly feed into the classification model. Here, we proposed DTI-SNNFRA, a
framework for identifying drug-target interaction (DTI), based on shared nearest
neighbor (SNN) and fuzzy-rough approximation (FRA). It uses a sampling technique to
collectively reduce the huge search space covering the available drugs, large number of
drugs targets and millions of interactions between them. DTI-SNNFRA operates on two
stages: first it uses SNN followed by a partitional clustering for sampling the search
space. Next, it computes degree of fuzzy-rough approximations and with proper degree
threshold selection for undersampling of the negative samples from all possible
interaction pairs between drugs and targets obtained in the first stage. Finally,
classification is performed using the positive and selected negative samples. We evaluate
the efficacy of DTI-SNNFRA using AUC (Area under ROC Curve), Geometric Mean,
and F1 Score. The model performs extremely well with high prediction score (around
0.95). The predicted drug-target interactions are validated through a existing
drug-target database (Connectivity Map (Cmap)).
1 Introduction
The drug development strategies aka drug repositioning, drug repurposing, drug
reprofiling, predicts the interaction between drug and target from the existing
drug-target database [1]. There are two types of drug-target interaction. One is called
competitive inhibitors which adhere themselves to the active site of the target to
suppress the reaction. Another type is allostoric inhibitors which prevents their target
to refrain from reactions by attaching themselves to the allosteric site of the target
which helps in killing pathogens to recover from the diseases. There exist several
synthesized compounds whose target profiles and effects are still unknown. The research
and findings about compounds properties, its reactions/responses to drugs and their
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targets have generated large and complex databases which needs efficient computational
methods to analyze and prediction of drug-target interaction. New drug design requires
more than 13.5 years and the cost exceeds 1.8 billion dollars [2], [3]; still it suffers from
the strong side effects on patients. Therefore the repositioning or repurposing of the
existing drug is helpful for pharmaceutical companies due to its known side-effects and
govt. approval. The drug repositioning usually reinvestigates those existing drugs which
were denied approval due to new therapeutic indications. The drug repurposing
processes [4] find the already authorized drugs and compounds for treating different
diseases. The practical laboratory experiments for identifying the interactions between
the drug and target are expensive as well as time-consuming and labor-intensive.
Instead of the in vitro experimental search, initially virtual screening is accomplished
and then possible candidates go through experimental verification. The in-silico based
prediction methods comprises docking simulations that need 3D structure analysis of
drug and target molecules to determine the potential binding sites. Despite the
excellent accuracy of this process, unavailability of proper 3D structure of drugs and
target, and long processing time hinders the docking simulation. Rather the
computational approach such as chemogenomics, assorted as ligand based, target based
and target-ligand is better in terms of expenses and time. In the chemogenomics the
chemical space and genomic space are mined together to find the potential compounds
such as imaging probes and drug leads [4]. Plenty of machine learning techniques based
on the similarity computation, matrix factorization, network models, features driven
and deep learning models for DTIs prediction are prevalent in the literature [1, 5]. The
similarity based approaches find how a drug (or target) or new drug is similar to the
known pairs based on the pharmacological similarity of drugs, genomic similarity of
protein sequences, similarity measures with respect to chemical based, ligand based,
expression based, side effect based and annotation based [6], [4]. The disadvantage of
this approach is that only a small number of interactions are available for comparison
and there are a large number of pairs for which interactions are not known. There is an
extensive collection of matrix factorization algorithms, in which [4], given an interaction
matrix Xn×m, the main goal is to decompose it into two lower order matrices, Yn×k and
Zm×k such that X = Y ZT with k < n,m which further will go through matrix
completion technique to compute the missing data that help in DTI prediction task. In
feature based [4] methods the drug and target vector are concatenated and append the
binary label for positive and negative interaction. Examples of features based method
include Bagging-based Ensemble method(BE-DTI) [7] that employs dimensionality
reduction and active learning. In [8], first feature subspacing and then three different
dimensionality reduction techniques are used to prepare training data for base learners,
namely decision tree and kernel ridge regression.Network-based models such as
TL-HGBI, DrugNet utilizes heterogeneous networks not only to predict the drug but
also recommend the way of treatments [4], [2]. In [9], the matrix inverse computation is
used to compute relevance grade between two nodes in a weighted network of
drug-target interactions. Deep learning based DTIs prediction [4], [10] utilize the
biological, topological and physico-chemical information of the drug and target to
compute vectors/matrices and have the capability to capture the inherent interactions
among the drugs and targets over the others state-of-the-art feature computation
methods and classifiers. Deep learning techniques sometimes can not be applied due to
the unavailability of sufficient information.
In this article, the feature-based method, called DTI-SNNFRA is proposed, under
the purview of chemogenomic approaches. Here individual drug and target are
represented by the feature vector. The drug-target interaction prediction task is a class
imbalance problems as most of the interaction pairs are unannotated and hence belongs
to the negative class. This pushes the classifiers to be more biased towards the major
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class, affecting the proper classification process. In light of the above context, we have
proposed a prediction framework for drug-target interaction in two phases that reduces
the search space considerably. In the first phase, for each drug-target pair, the shared
nearest-neighbors (SNN) of this drug are accumulated. These collected drugs are then
clustered and the centroid from each cluster is taken as a representative. Representative
targets are also determined in a similar way. These representative drugs and targets are
used to form drug-target pairs that are fewer in number and are probable candidates for
possible interactions. The pairs obtained in this way are treated as negative interaction
pairs. The positive interaction pairs are taken from the given drug-target interaction
matrix. Despite the reduction in search space, the obtained training set created in this
way is highly imbalanced. In order to encounter this problem, we have utilized
fuzzy-rough approximation scores and one threshold value to perform undersampling of
the negative samples. If the number of negative interaction pairs are considerably less
than the positive interaction pairs then oversampling is carried out by Adaptive
Synthetic Sampling Method (ADASYN). This produces a reduced and balanced training
set which can be used by any general classifiers. We have applied several state-of-the-art
classifiers such as SVM, decision tree, random forest for this task to find the accuracy of
predicted interactions.
In section 2 of this article, dataset utilized in this work along with method and
algorithms are explained. In section 2.3, a brief description and definition of the
fuzzy-rough set based lower and upper approximation is outlined. In section 3, results
and discussions are presented and finally section 4 draws the conclusion.
2 Materials and methods
In this section, we describe the datasets used in this work, key ideas of our algorithms
and some background of fuzzy-rough set. The building block of proposed DTI-SNNFRA
method is shown in Figure 1.
2.1 Dataset Preparation
In this article, the interaction data is taken from the DrugBank database [11] (version
4.3, released on 17 Nov. 2015) and from dataset mentioned in [12]. For dataset1, the
number of drugs are 5877, targets are 3348 and the number of interactions between the
drugs and targets are 12674. Every drug and target are represented by the feature
vectors. The feature vector of each drug has been computed by Rcpi [13] package and
the PROFEAT [14] web server which is represented by constitutional, topological and
geometrical descriptors. The feature vector of each target has been computed using
amino acid composition, pseudo-amino acid composition and CTD (composition,
transition, distribution) descriptors, among others. The number of features for drug and
target of dataset1 are 193 and 1290, respectively. In the dataset2, every drug is
represented by a binary vector where each element of this vector denotes the presence
and absence of one of 881 chemical substructures. Each target of dataset2 is also
represented by a binary vector where each element denotes the presence and absence of
876 different protein as mentioned in Pfam database [15]. The high dimensional features
vector of drug and target are concatenated to represent the drug- target pair features
vector and can be represented for dataset1 as:
{d1, d2, ....., d193, t1, t2, ....., t1290}
These drug-target pairs features vectors are then normalized in the range [0, 1] by
min-max method for avoiding bias towards any feature.
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Fig 1. Building block of proposed DTI-SNNFRA Method
2.2 Workflow of the proposed framework
In this section the basic steps of our proposed method are described:
2.2.1 Step 1: Finding positive and negative drug-target pairs and spiliting
After the normalization, only the drugs and targets which have known interactions in
the interaction matrix are used to form the positive samples for classifiers to predict
new drug target interactions. But the number of negative samples derived from the
interaction matrix is really a big number. Note that the high dimensionality and large
number of samples may have diverse effect in the prediction task. The proposed method
can tackle both the issues. Finding characteristically similar drugs and targets using the
nearest-neighbor query facilitates new drug-target prediction. Determination of the
nearest-neighbors using similarity distance measures are sensitive to the dimensionality
and the distribution of the dataset. The popular similarity function L1 and L2 in
Minkowski space infers the fact that for a certain data distribution, the relative
difference of the distances of the closest and farthest data points of an independently
selected point goes to 0, as the dimensionality increases. For this reason, the primary
distances functions like L1, L2, and cosine etc. are not suitable for high dimensional
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data. In this context, Shared Nearest Neighbor (SNN) based ranking is strong in higher
dimensions than primary distances [16]. Assume the dataset S consisting of n = |S|
objects and k ∈ N+. For each individual drug (or target), let NNk(x) ⊆ S represents
k-nearest-neighbors of x ∈ S as computed using L2 similarity measure. The overlap
between the computed shared nearest neighbors sets of the objects x and y is
represented as:
SNNk(x, y) = |NNk(x) ∩NNk(y)| (1)
The Algorithm 1, provides the procedure to compute shared nearest neighbors and the
Algorithm 2, outlines how the training dataset is prepared for classifiers.
Suppose, the total number of drug and targets are M and N . Assume drug di,i∈M
interacts with target tj,j∈N . Now for this di, the indices of all drugs in⋃
SNNk(di, dr),∀r ∈M and i 6= r are identified and assigned to snnDi. Similarly, for
the target tj , the indices of all targets in
⋃
SNNk(tj , tr),∀r ∈ N and j 6= r are
identified and assigned to snnTj . Then all the drugs and targets in snnDi and snnTj
are clustered using the k-medoids clustering and centroids are selected as a
representatives of snnDi and snnTj . The Calinski-Harabasz criterion is used here to
determine the correct number of clusters. Now these representatives drugs and targets
from snnDi and snnTj are taken to make cartesian product pairs. Subsequently,
corresponding drug vector and target vector are concatenated for each cartesian product
pair which in turn are included in negative samples set. Selection of the negative
samples obtained by the above shared nearest neighbors approaches reduces the
inclusion of the irrelevant drug-target pairs. For example, in dataset1, the number of
approved drug-target pairs are 12674 and number of all possible pairs from which
interaction may be predicted are 19663522. So, handling these huge number of negative
samples pairs against 12674 positive samples are very difficult. The number of shared
nearest neighbors of one drug or target, where this one drug or target is taken from each
positive drug-target pair, with all others remaining drugs and targets, is rather
producing fewer number of drug-target pairs for negative samples. Therefore, SNN
based initial selection can be used to reduce the large number of irrelevant negative
drug-target pairs. For dataset1, the number of drug-target pairs from the pool of
19663522 pairs are 45933 which indicates 427 times samples removal. Positive and
negative set of samples thus obtained are divided into m and n groups, respectively.
2.2.2 Step 2: Decision table preparation and average approximation
degree computation
Each group from the negative set, say, nj is taken m times with m group from the
positive set and m number of decision table are prepared. Now each decision table are
used to compute the fuzzy rough upper approximation degree of each sample in the nj
group. The m number of upper approximation degree of each sample in the nj group
are then taken for average upper approximation degree computation.
2.2.3 Step 3: Under sampling based on approximation degree
One grade membership is computed for every negative sample with respect to all
positive interactions as per the Algorithm 3. The fuzzy-rough upper approximation
degree as mentioned in Section 2.3 is computed here which possibly indicates the
possible interaction degree value between 0 to 1 scale. Now, one threshold value near 1
can be assumed to select many samples whose fuzzy-rough upper approximation degree
are greater than or equal to that threshold in order to augment positive samples set.
Another one threshold value near 0 can be assumed to select many samples whose
fuzzy-rough upper approximation degree are less than or equal that threshold in order
to undersample the negative samples.
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2.2.4 Step 4: Oversampling, if required
If the number of negative samples as selected in Step 3 are less than the total positive
samples then oversampling using Adaptive Synthetic Sampling Method (ADASYN) [17],
prior to feed into the classification or regression model, can be used to balance the
positive negative ratio.
2.2.5 Step 5: Interaction prediction
Dataset as obtained in step 4 are then used for classification or regression for predicting
the interaction of the pairs belong to the negative set.
2.3 Fuzzy rough set
Assume that the drug-target pairs as obtained by given interaction matrix and SNN
based initial filtering constitute a decision table is called IT . In this table, every row is
denoted by m numbers of features i.e. C = {fi : 1 ≤ i ≤ m} and one decision attribute
D = {d}.
In this IT , how two objects are indiscernible are determined by calculating fuzzy
indiscernibility relation (FIR). Subsequently, this indiscernibility relation is taken to
determine fuzzy-rough lower and upper approximation. The fuzzy lower and upper
approximations using fuzzy similarity relation (either fuzzy equivalence or tolerance
relation), in pursuance of Radzikowska’s model, to approximate a concept Y are defined
as [18]:
µRPY (x) = inf
y∈IT
I(µRP (x, y), µY (y)) (2)
µRPY (x) = sup
y∈IT
T (µRP (x, y), µY (y)) (3)
Here, in equations 2 and 3, I indicates a fuzzy implicator, T denotes a t-norm and
RP is the fuzzy similarity relation computed by the features subset P ⊆ C. To calculate
the fuzzy similarity relation RP , which is used in fuzzy lower and upper approximations
as mentioned in the equation 2, 3, with respect to features subset P ⊆ C the following
equation may be taken.
µRP (x, y) =
⋂
f∈P
{µRf (x, y)} (4)
Here, µRf (x, y) denotes the similarity degree between object x and y with respect to
feature f . Some examples of fuzzy similarity relations are given below:
µRf (x, y) = 1−
|f(x)− f(y)|
|fmax − fmin| (5)
µRf (x, y) = exp(−
(f(x)− f(y))2
2σ2
) (6)
µRf (x, y)
= max(min
(
(f(y)− (f(x)− σf ))
(f(x)− (f(x)− σf ))
,
(f(x) + σf )− f(y))
(f(x) + σf )− f(x))
)
, 0) (7)
where σ2 stands for the variance of feature f .
Upper approximation degree computation:
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In Figure 1, the fuzzy rough upper approximation degree is computed as follows:
1. Computing fuzzy indiscernibility relation of conditional attributes using the
lukasiewicz t-tnorm and tolerance relation as mentioned in section 2.3.
2. Computing fuzzy indiscernibility relation of decision attribute using the its crisp
relation.
3. Computing fuzzy upper approximation using the lukasiewicz t-tnorm as per the
equation 3.
This fuzzy upper approximation degree can be used to select the samples from the
negative samples set.
Algorithm 1: sharedNN
Input: D = feature matrix for the drug
T = feature matrix for the target
Output: shared nearest neighbors represented by feature vectors
k ← Neighborhood size
X ← D or T
n← sampleSize(X)
distances = pairWiseDistance(X)
sorted, indexes = sort(distances, ascendOrder)
for i← 1 to n do
sharedNN = []
for j ← 1 to n do
C = intersect(indexes(i,2:k+1),
indexes(j,2:k+1))
sharedNN = sharedNN ∪ X(C)
Algorithm 2: Dataset Preparation
Input: DT = drug-target interaction matrix
D = feature matrix for the drug
T = feature matrix for the target
Output: labeled TrainingDataSet
P ← { } % P = positive samples set
N ← { } %N = negative samples set
for i← 1 to m do
for j ← 1 to n do
if DT (i, j)=1 then
P ← P ∪ concat(drugV eci, targetV ecj)
tempDi ← sharedNN(drugV eci)
snnDi ← optimalKmedoidsCentroids(tempDi)
tempTj ← sharedNN(targetV ecj)
snnTj ← optimalKmedoidsCentroids(tempTj)
N ← N ∪ cartesianProductPairConcat(snnDi, snnTj)
TrainingDataset ← P ∪N
3 Results and discussions
3.1 Performance metrics
This section explains the experimental results by using three metrics referred to as
ROC-AUC scores, F1 scores and Geometric Mean scores [19]. The ROC-AUC provides
a single score used to compare the models. It ranges from 0 to 1 where 1 indicates the
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Algorithm 3: Average FRUA degree computation and sampling.
Data: Imbalanced TrainingDataset I with M samples {xi, yi} where i = 1 to M and
xi is an d-dimensional vector in drug-target pair feature space and yi ∈ {0, 1}.
Assume Mp and Mq represent number of minority and majority class samples
respectively, such that Mp ≤Mq and Mp +Mq =M
Result: BalancedTraingDataset
Begin
function upperAproxCalc(decisionTable)
begin
uDegree→ {}
objCount→ sizeof(decisionTable)
for k ← 1 to objCount do
uDegree(k)← µR
C
Y (decisionTablek)
here C : conditional attributes set as per equation 3
end
split(Mp)→ m groups
split(Mq)→ n groups
totalNoGroupPair ← m× n
allGroupPairIndices← cartesianProduct(seq(1 : m), seq(1 : n))
for i← 1 to totalNoGroupPair do
allGroupPairIndices(i)→ (groupIndexOfm, groupIndexOfn)
decisionTablei →
(PgroupIndexOf
m
with positive label) ∪ (NgroupIndexOf
n
with negative label)
Ui ← upperAproxCalc(decisionTablei)
Ui ← upperApproxDegree of PgroupIndexOf
m
∪
upperApproxDegree of NgroupIndexOf
n
FRUA : ( 1
m
∑
( upperApproxDegree of NgroupIndexOf
n
|
for each groupIndexOfn ∈ seq(1 : n) and ∀ groupIndexOfm))
Sampling:
tp and tq are the thresolds for Mp and Mq
Z → ∅
for x ∈Mq do
if FRUA(x) ≥ tp then
Mp ←Mp ∪ x
if FRUA(x) ≤ tq then
Z ← Z ∪ x
BalancedTraingDataset= ADASY N(Mp ∪ Z)
End
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A. Dataset 1 B. Dataset 2
Fig 2. (A) and (B) represents the performance on two datasets. The AUC, F1 and
G-mean scores under the classification models of decision tree, random forest and
support vector machine, respectively are demonstrated using various sampling methods.
perfect model and 0.5 represents a model having no prediction skill and the values less
than 0.5 indicate that the prediction skill is worse than no skill. This ROC-AUC
performance evaluation is unconcerned for high imbalanced dataset. How well the
positive class and the negative class are predicted by a model are represented by the
sensitivity and specificity. The sensitivity and specificity together can be integrated into
a single score called geometric mean is represented by sqrt(Sensitivity * Specificity)
where the Sensitivity = TruePositive / (TruePositive + FalseNegative) and
Specificity=TrueNegative / (FalsePositive + TrueNegative). The F1 score can be used
to achieve the balance between Precision and Recall. It is also used where class
imbalance due to large number of negative samples are present. All three scores are
calculated here using 5-fold cross-validation and average AUC, F1 score and G-mean
score are computed. Note that the datasets 1 and 2 as mentioned in section 2 are used
for prediction.
3.2 Five sampling methods and EnsemDT and EnsemKRR vs
proposed method
The prediction scores of the DTI-SNNFRA method has been compared with the five
sampling techniques known as SMOTE, ADASYN, RUS, SMOTEENN, SMOTETomek
respectively in Fig. 2 using the SVM, Decision Tree (DT), and Random Forest(RF)
Classifiers. Also the AUC score of the DTI-SNNFRA method is compared with
EnsemDT and EnsemKRR [8] in Table 1. The list of parameters for RF are as follows:
nEstimators = 100, gini criterion function is used to measure the quality of a split.
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Table 1. Comparison of proposed method with EnsemDT and EnsemKRR
Methods
Dataset 1
AUC
Dataset 2
AUC
EnsemDT, SVD 0.899 0.914
EnsemDT, PLS 0.902 0.898
EnsemDT, LapEig 0.901 0.914
EnsemKRR, SVD 0.942 0.931
EnsemKRR, PLS 0.941 0.930
EnsemKRR, LapEig 0.941 0.930
Proposed
DT 0.955 0.930
RF 0.961 0.943
SVM 0.951 0.860
Table 2. Drug-target interactions by proposed method
Drug Target FruaScore Drug Target FruaScore
DB04094 Q9Y296 0.933385 DB00839 Q09428 0.814468
DB03750 P0CG47 0.933299 DB00476 P28335 0.810978
DB03988 Q9Y296 0.933073 DB00450 P35462 0.806337
DB03320 Q9Y296 0.932387 DB00776 P35498 0.804604
DB08242 P0AEK4 0.932214 DB00929 P43119 0.803532
DB08137 P0AEK4 0.932189 DB00433 P35462 0.802923
DB07153 P16184 0.932128 DB00794 Q14524 0.799097
DB00992 Q9Y296 0.932054 DB00917 P21731 0.798244
DB04789 P16184 0.932053 DB01121 Q14524 0.795084
DB07000 P0AEK4 0.932018 DB00645 Q14524 0.793230
DB04197 Q9Y296 0.932002 DB00850 P35367 0.764447
DB07281 P0AEK4 0.931912 DB04846 P08913 0.759809
DB03448 P0A884 0.931780 DB00782 P08172 0.758948
DB04796 P14867 0.931678 DB01365 P08913 0.751881
DB02456 P0A884 0.931636 DB01121 Q9NY46 0.751538
DB04680 P0CG29 0.931635 DB03719 P30542 0.747386
DB01248 P07437 0.922451 DB00670 P08172 0.745866
DB00518 P07437 0.919137 DB07954 P30542 0.744886
DB00391 P00915 0.915100 DB00794 Q9Y5Y9 0.730465
DB01248 Q13509 0.914888 DB00776 Q9Y5Y9 0.710952
DB01248 P68363 0.911210 DB00252 Q9Y5Y9 0.709006
DB05294 Q15303 0.904014 DB00999 Q08460 0.594489
DB00361 P68363 0.897636 DB01119 Q08460 0.589146
DB01121 P35499 0.824893 DB00356 Q08460 0.583733
DB04846 P07550 0.816920 DB03719 P29274 0.556650
The minimum number of samples required to split an internal node is
minSsamplesSplit = 2. The maximum depth of the tree is decided as nodes are
expanded until all leaves are pure or until all leaves contain less than
minSsamplesSplit samples. For DT the criterion function and the minSsamplesSplit
parameters are same as RF. The number of features for both the RF and DT are equal
to maxFeatures = sqrt(nFeatures). For SVM classifier, the kernel type used is linear
and regularization parameter C = 1.0. The Fig. 4 (A) and (B) demonstrates the
variation of the AUC score of the decision tree with respect to two hyperparameters
called tree depth and max feature. In Fig. 4 (C), one heatmap has been shown which is
computed by the grid search based hyperparameters(n estimators, max depths) selection
of the random forest model.
To prepare negative drug-target pairs, the number of nearest neighbors are 11 which
later used to compute the shared nearest neighbors. Total number of features for the
drug-target pairs are 1483 for dataset1 ( or 1757 for dataset2) which is very high. We
have transformed these high-dimensional data into lower dimensions by the PCA for
computing the approximation degree using fuzzy-rough set.
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Table 3. Drug target interaction verification and new interaction by the proposed
method
Correct predictions New interactions
Target name:
Serine
hydroxymethyl
transferase,
cytosolic
D
ru
gs
Mimosine Pyridostigmine
Pyridoxal phosphate Willardiine
Glycine N-acetylhistamine
Triglu-5-formyl-tetrahydrofolate N-BENZOYL-D-ALANINE
N-Pyridoxyl-Glycine-5-
Monophosphate
Tyrosine
Target name:
Monoamine
oxidase D
ru
gs
Amphetamine Diethylpropion
Phentermine Ethinamate
Tranylcypromine Alprenolol
Phenelzine Phenylalanylmethylchloride
Selegiline Probenecid
Drug name:
alpha-D-
glucose
6-phosphate
T
ar
ge
ts
Glucose-6-phosphateisomerase Peptide deformylase
Glycogen phosphorylase,
muscle form
Adenylate kinase
isoenzyme 1
Aldose reductase Adenosylhomocysteinase
Glutamine–fructose-6-phosphate
aminotransferase [isomerizing]
Phosphoheptose isomerase
Hexokinase-1
Low molecular weight2
phosphotyrosine
protein phosphatase
Drug name:
Adenosine-5-
Diphospho-
ribose
T
ar
ge
ts
MutT/nudix family protein Enoyl-[acyl-carrierprotein]
reductase [NADH] FabI
p-hydroxy-
benzoate hydroxylase
GDP-mannose6-dehydrogenase
Glyceraldehyde-3-
phosphate dehydrogenase
RNA-directed
RNA polymerase
Lactaldehyde reductase Serine hydroxymethyl-
transferase
Elongation factor 2 Bifunctional protein BirA
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3.3 Feature selection and comparisons
In Fig. 3, the prediction scores in term of AUC values have been shown for both
datasets considering feature selection and no feature selection. These prediction scores
have been computed by RUSBoostClassifier as it mitigates the class imbalancing
problem during learning by the random under-sampling the samples at each iteration of
boosting. The training and testing ratio for RUSBoostClassifier is taken here as 70:30.
In RUSBoostClassifier, number of base learner and learning rate used as parameters are
50 and 0.1, respectively. For feature selection, the features importance scores have been
computed using XGBoost and random forest. Random forest assumes the feature
importance is the average of all decision tree feature importance. These two feature
importance computation methods splits the datasets where positive and negative
samples appear in approximately equal numbers. All the positive and negative groups
pairs individually taken by the XGBoost and random forest classifiers for computing the
feature importance. Finally, average feature importance scores are computed and top
100 features are taken for prediction. The average execution time, without feature
selection, over 50 thresholds for the dataset1 and dataset2 are 617.66 sec. and 232.07
sec. respectively. When feature selection is considered, these average execution time for
the dataset1 and dataset2 are 232.07 sec. and 77.61 sec. respectively.
3.4 Sensitivity vs number of base learners and classification
errors
In Fig. 3, two plots represent the M vs Sensitivity graph for both datasets where M
represents the number of base learner that ranging from 1 to 50. This experiment is
carried out for few thresolds values. The classification errors means the proportion of
samples that the classifier misclassified are also reported in Fig. 3.
3.5 Drug-target interaction of the proposed method
In Table 3, few interactions between the drugs and targets have been provided. To test
the efficacy of the proposed method, we have omitted several known interactions from
training data. Then training with the remaining data and verifying the prediction of the
previouly omitted data has been carried out for many pairs. The seven drugs for Serine
hydroxymethyltransferase, cytosolic are predicted correctly and five are listed in Table 3,
also five new interactions have been shown. In similar way, in Table 3 , few correct
predictions and few new intearctions are shown for the drug named Monoamine oxidase.
Also in the Table 3, few correct prediction and new interaction have been mentioned for
the the two targets called alpha-D-glucose 6-phosphate and Adenosine-5-
Diphosphoribose. In Fig. 5, some drug-target interactions have been shown and few
links are showing the interactions between the treatments area and drugs.
3.6 Drug-target interaction validation
To verify our prediction results, we have used the Connectivity Map (Cmap) [20]
prediction results provided by the Broad Institute. The drug name and target name in
the Drugbank dataset have the different representation in Cmap. To match our
prediction results with the Cmap, some conversion between Drugbank and Cmap have
been done using the webchem R package [21]. This R package retrieves the chemical
information from the web using a suite of 14 web services. Our prediction results of
drug-target pairs with respect to Drugbank dataset are taken by webchem which only
fetch the information from Wikidata. Due to the lack of information in the suite of web
services except Wikidata as provided by webchem R package, we have obtained few
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Fig 3. (A) and (B) represent Threshold vs AUC graph for dataset 1 and dataset 2
using feature selection and without feature selection respectively. (C) and (D) represent
M vs Sensitivity plots for both datasets using five thresholds. (E) and (F) represent
classification errors for both Dataset 1 and Dataset 2, respectively using one threshold.
matching between our prediction and Cmap predictions. In Table 2, a list of 50 pairs of
the drugs and targets are given which are the prediction of our method and also
validate the Cmap prediction results. Some drug-target pairs in Table 2, as predicted by
our proposed method, have the interactions as (DB01248, P07437), (DB04846, P07550),
(DB00839, Q09428), (DB00450, P35462), (DB00776, Q9Y5Y9), (DB00776, P35498) are
also reported in [22], [23], [24], [25], [26] and [25] respectively. Thirty-four boldface
drug-target pairs in the Table 2 are the result of our prediction model are also validated
by the Cmap.
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A B
C
Fig 4. (A) and (B) represent the hyperparameters of decision tree called max feature
and tree depth vs AUC graph for dataset 1, respectively. In (C), the hyperparameters of
random forest along with the AUC scores are shown in the heatmap.
4 Conclusion
In this article a novel computational approach for drug-target interaction prediction is
presented utilizing existing drug-target data. There are two major caveats in this
domain: massive amount of drugs and targets creating a huge search space and highly
imbalanced drug-target interactions dataset as there are very small number of
drug-target interactions unveiled so far. Thus, the size of the negative samples is much
higher than size of the positive samples. Here, we have used shared nearest neighbours
rather than taking a fixed number of nearest neighbours as it will be more effective in
higher dimensional dataset. The reason behind this is that typically, the size of the
overlapped items within the neighborhoods of a pair of drugs or targets inside the same
group is substantially larger than the neighborhoods of a pair of drugs or targets
belonging to different groups. Moreover, to reduce the the curse of imbalanced dataset,
these shared nearest neighbors are further grouped by k-medoids and the representative
centroids of k-medoids for the drug and target are considered as new possible
drug-target interaction pairs for each known drug-targets pair. Additionally, in order to
deal with imbalanced dataset further, we have computed the degree of fuzzy-rough
upper approximation of all possible interaction pairs in the negative samples set to
perform undersampling. Thereafter, selecting a threshold of the computed degrees, size
of the negative and positive samples sets were balanced. This upper approximation
degree based undersampling of the negative set causes improvement of the prediction
scores. The computation cost of degree of the fuzzy-rough upper approximation is
challenging as the dimension interaction pairs is extremely high. The execution time of
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Fig 5. Drug target interaction and some diseases on which few drugs works
this fuzzy-rough upper approximation degree is directly proportional to the number of
features. Therefore, further investigation on fuzzy-rough set based feature selection
followed by fuzzy-rough upper approximation computation may improve the prediction
score. Instead of using a single threshold for undersampling, multiple threshold based
undersampling may be investigated for tackling the curse of imbalanced datasets.
Moreover, oversampling of the positive samples to balance the number negative samples
and the number positive samples may be explored to improve the prediction score.
The proposed method DTI-SNNFRA not only selects the possible candidates using
shared nearest neighbors in the first stage but also has the ability to assign the grade of
interaction through fuzzy-rough upper approximation degree computation. The
threshold based undersampling and balancing the positive and negative interaction pairs
leads to a robust classification model. We believe that DTI-SNNFRA may be a
promising framework for drug-target interaction prediction.
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